Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Follow-Up Study to Add Whole Brain Radiotherapy (WBRT) to Standard Temozolomide Chemo-Radiotherapy in Newly Diagnosed Glioblastoma (GBM) Treated With 4 Weeks of Continuous Infusion Plerixafor

Next Previous
Trial Profile

A Follow-Up Study to Add Whole Brain Radiotherapy (WBRT) to Standard Temozolomide Chemo-Radiotherapy in Newly Diagnosed Glioblastoma (GBM) Treated With 4 Weeks of Continuous Infusion Plerixafor

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plerixafor (Primary) ; Temozolomide
  • Indications Glioblastoma; Glioma; Gliosarcoma; Primitive neuroectodermal tumours
  • Focus Therapeutic Use

Most Recent Events

  • 04 Jun 2024 Results (n=17) assessing efficacy of Plerixafor in combination with WBRT in newly diagnosed high grade glioma, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 27 Mar 2024 Status changed from recruiting to active, no longer recruiting.
  • 13 Apr 2023 Planned primary completion date changed from 1 Jan 2023 to 26 Jan 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top